Replies to post #179808 on Biotech Values

[DewDiligence]

B-I submits BLA for Pradaxa antidote, Idarucizumab:

http://finance.yahoo.com/news/boehringer-ingelheim-submits-biologics-license-130000907.html

Idarucizumab has BTD from the FDA.

Note: Factor Xa antidotes such as PTLA’s Andexanet alfa don’t work on Pradaxa, which is a direct thrombin inhibitor, not an FXa inhibitor.

See #msg-102641221 for related info.